Nonoperating Income (Expense) of Lipocine Inc. from 31 Mar 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Lipocine Inc. quarterly and annual Nonoperating Income (Expense) in USD history and change rate from 31 Mar 2017 to 31 Dec 2025.
  • Lipocine Inc. Nonoperating Income (Expense) for the quarter ending 31 Dec 2025 was $145,718, a 38% decline year-over-year.
  • Lipocine Inc. Nonoperating Income (Expense) for the twelve months ending 31 Dec 2025 was $744,074, a 36% decline year-over-year.
  • Lipocine Inc. annual Nonoperating Income (Expense) for 2025 was $744,074, a 36% decline from 2024.
  • Lipocine Inc. annual Nonoperating Income (Expense) for 2024 was $1,164,068, a 26% decline from 2023.
  • Lipocine Inc. annual Nonoperating Income (Expense) for 2023 was $1,579,630, a 16% increase from 2022.
Source SEC data
View on sec.gov
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Change (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Change (%)

Lipocine Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $744,074 $145,718 -$90,988 -38% 01 Oct 2025 31 Dec 2025 10-K 10 Mar 2026 2025 FY
Q3 2025 $835,062 $174,208 -$237,447 -58% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $1,072,509 $198,637 -$25,778 -11% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $1,098,287 $225,511 -$65,781 -23% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $1,164,068 $236,706 -$74,949 -24% 01 Oct 2024 31 Dec 2024 10-K 10 Mar 2026 2025 FY
Q3 2024 $1,239,017 $411,655 +$19,259 +4.9% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $1,219,758 $224,415 -$182,561 -45% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $1,402,319 $291,292 -$177,311 -38% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $1,579,630 $311,655 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $392,396 -$97,810 -20% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $406,976 -$488,778 -55% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $468,603 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q3 2022 $490,206 01 Jul 2022 30 Sep 2022 10-Q 08 Nov 2023 2023 Q3
Q2 2022 $895,754 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q3 2018 $106,016 -$171,827 -261% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2018 2018 Q3
Q2 2018 $91,091 -$141,943 -279% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2018 2018 Q2
Q1 2018 $82,285 -$130,640 -270% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2018 2018 Q1
Q3 2017 $65,811 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $50,852 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $48,355 01 Jan 2017 31 Mar 2017 10-Q 07 May 2018 2018 Q1

Lipocine Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $744,074 -$419,994 -36% 01 Jan 2025 31 Dec 2025 10-K 10 Mar 2026 2025 FY
2024 $1,164,068 -$415,562 -26% 01 Jan 2024 31 Dec 2024 10-K 10 Mar 2026 2025 FY
2023 $1,579,630 +$218,210 +16% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $1,361,420 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.